Roger D. Kornberg

Professor Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University, Stanford, California. He has been a member of the faculty of Stanford University since 1972. Prior to that, he was a professor at Harvard Medical School. Professor Kornberg is a renowned biochemist, and in 2006, he was awarded the Nobel Prize in Chemistry in recognition for his studies of the molecular basis of eukaryotic transcription, the process by which DNA is copied to RNA.

Professor Kornberg joined Omnix at inception. He has served as a director of Protalix since 2008; he has served as a director of OphthaliX Inc. since 2012; and of Biozone Pharmaceuticals, Inc. since 2014. Professor Kornberg served as a director of Teva Pharmaceuticals from 2007 through 2013, and he also serves as the Chief Scientist and a director of Biozone Pharmaceuticals.

Professor Kornberg is also the recipient of several awards, including the 2001 Welch Prize, the highest award granted in the field of chemistry in the United States, and the 2002 Leopold Mayer Prize, the highest award granted in the field of biomedical sciences from the French Academy of Sciences. He received his B.Sc. in Chemistry from Harvard University and his PhD in Chemistry from Stanford University. He holds honorary degrees from universities in Europe and Israel, including the Hebrew University in Jerusalem, where he currently is a visiting professor.

As Chairman of the BoD, Dr. Schuh is the architect of Omnix execution and milestone-driven strategy to achieve the company’s future goals.